Amylin, a peptide hormone known for its aggregation in the pancreas during type-2 diabetes, may trigger several Alzheimer's disease (AD)-related pathological mechanisms, including neuroinflammation and cognitive deficits. Although it has been reported that amylin can affect tau pathology in an AD mouse model, the cellular mechanisms underlying the interaction between tau and amylin remain poorly understood.
This research, published in the
Genes & Diseases journal by a team from University of South Florida, analyzed the interaction between amylin and tau pathology to uncover how diabetes can influence the risk of developing AD.
Initially, the researchers administered streptozotocin (STZ) and/or amylin peripherally to the PS19 model of tauopathy at 3 months and evaluated the mice at 6 months of age. The team found that STZ reduced body weight gain, increased blood glucose levels, impaired motor performance, and improved fear-conditioned memory in PS19 mice, hallmarks often associated with neurodegenerative progression.
Remarkably, both amylin and STZ administration not only induced the emergence of tau pathology in the pancreas, but also led to a decline in the number of lysosomes in pancreatic islets. Interestingly, mice treated with amylin and STZ also developed robust tau pathology associated with lowering lysosomal cathepsin D (CatD) levels in the visual cortex, indicating impaired protein clearance mechanisms. Surprisingly, the pancreas also exhibited tau pathology in diabetic mice, especially in those receiving both STZ and amylin, alongside reduced lysosomal markers such as LAMP1 in islet cells. This finding underscores the intricate and bidirectional relationship between diabetes and AD.
In summary, this study demonstrates that amylin, in synergy with diabetes, exacerbates tau pathology by impairing lysosomal activity in the visual cortex. Overall, the findings of this research enhance our understanding of the cellular pathways through which amylin may serve as a link in the pancreas-brain axis during diabetes, influencing the risk of developing tau pathology.
Reference
Title of Original Paper: Amylin exacerbates tau pathology in the visual cortex of diabetic mice by impairing lysosomal activity
Journal: Genes & Diseases
Genes & Diseases is a journal for molecular and translational medicine. The journal primarily focuses on publishing investigations on the molecular bases and experimental therapeutics of human diseases. Publication formats include full length research article, review article, short communication, correspondence, perspectives, commentary, views on news, and research watch
DOI: https://doi.org/10.1016/j.gendis.2025.101602
Funding Information:
US National Institutes on Aging (No. AG057290)
# # # # # #
Genes & Diseases publishes rigorously peer-reviewed and high quality original articles and authoritative reviews that focus on the molecular bases of human diseases. Emphasis is placed on hypothesis-driven, mechanistic studies relevant to pathogenesis and/or experimental therapeutics of human diseases. The journal has worldwide authorship, and a broad scope in basic and translational biomedical research of molecular biology, molecular genetics, and cell biology, including but not limited to cell proliferation and apoptosis, signal transduction, stem cell biology, developmental biology, gene regulation and epigenetics, cancer biology, immunity and infection, neuroscience, disease-specific animal models, gene and cell-based therapies, and regenerative medicine.
Scopus CiteScore: 8.4 |
Impact Factor: 9.4
# # # # # #
More information: https://www.keaipublishing.com/en/journals/genes-and-diseases/
Editorial Board: https://www.keaipublishing.com/en/journals/genes-and-diseases/editorial-board/
All issues and articles in press are available
online in
ScienceDirect (
https://www.sciencedirect.com/journal/genes-and-diseases).
Submissions to
Genes & Disease may be made using
Editorial Manager (
https://www.editorialmanager.com/gendis/default.aspx ).
Print ISSN: 2352-4820
eISSN: 2352-3042
CN: 50-1221/R
Contact Us: editor@genesndiseases.com
X (formerly Twitter): @GenesNDiseases (
https://x.com/GenesNDiseases)